Two major obstacles in drug development are drug target validation and determining drug effectiveness and safety. The Infinium DrugDev Consortium Array has been designed to provide comprehensive coverage of the druggable genome (human drug targets), and adsorption, distribution, metabolism, and excretion (ADME) genes to improve drug development studies and overcome these obstacles. Specifically the DrugDev Consortium Array has been designed to enable target validation earlier in the development pipeline, identification of off-target effects, repurposing of existing drugs, and stratified medicine studies. Presenters: Aroon Hingorani, Professor, Chair of Genetic Epidemiology Institute of Cardiovascular Science, University College London John Overington, Visiting Professor of Computational Chemical Biology Institute of Cardiovascular Science, University College London Anna Gaulton, PhD, Senior Data Integration and Development Officer – ChEMBL European Bioinformatics Institute, Hinxton Infinium DrugDev Consortium Array http://www.illumina.com/content/dam/illumina-marketing/documents/products/product_information_sheets/infinium-drug-dev-consortium-array-product-information-sheet-1070-2015-002.pdf View related video Illumina Arrays: Next-Gen GWAS Now https://www.youtube.com/watch?v=nOA_UdtTCbs&list=PL3530CBD61840BA10 View related information Human Genotyping http://www.illumina.com/techniques/microarrays/human-genotyping.html Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc